Advanced search
Publication Cover
Acta Clinica Belgica
International Journal of Clinical and Laboratory Medicine
Volume 51, 1996 - Issue 4
Submit an article Journal homepage
32
Views
18
CrossRef citations to date
0
Altmetric
Review Article

Cytochrome P450: Genetic Polymorphism and Drug Interactions

F.M. BelpaireHeymans Institute of Pharmacology, University of Gent Medical School, De Pintelaan185, B-9000Gent, Belgium
&
M.G. BogaertHeymans Institute of Pharmacology, University of Gent Medical School, De Pintelaan185, B-9000Gent, Belgium
Pages 254-260 | Published online: 16 May 2016

References

  • Dumont E, Belpaire F. Genelic polymorphism of drug metabolism. Acta Clin Belg. 1989; 44: 15760.
  • Bcrtilsson L. Geographical/Interracial differences in polymorphic drug oxidation. Current status of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokin. 1995; 29: 192–209.
  • Brosen K. Recent developments in hepatic drug oxidation: Implications for clinical pharmacokinetics. Clin Pharmacokin. 1990; 18: 220–39.
  • Gonzalez FJ, Idle J. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokin. 1994; 26: 59–70.
  • Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol. 1994; 46(suppl): 409–15.
  • Murray M. P450 enzymes: Inhibition mechanisms, genelic regulation and effects of liver disease. Clin Pharmacokin, 1992;23:132–46.
  • Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994; 46(suppl): 417–24.
  • Nelson D. Kamataki T, Waxman D et al. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12: 1–51.
  • Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994; 30: 251–9.
  • KivistO KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokin. 1994, 27: 1–5.
  • Keogh A, Spratt P, McCosker MB, MacDonald P, Mundy BS, Kaan A. Ketoconazole to reduce the need for cyclosporin after cardiac transplantation. N Engl J Med. 1995; 333: 628–32.
  • Bailey DG, Arnold JMO, Spcncc JD. Grapefruit juice and drugs. How significant is the interaction? Clin Pharmacokin. 1994; 26:91–8.
  • Okey AB. Enzyme induction in the cytochrome P-450 system. Pharm Ther. 1990; 45: 241–98.
  • Birkett DJ, Mackenzie PI, Veronese ME, Miners JO. In vitro approaches can predict human drug metabolism. TIPS. 1993; 14: 292–4.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.